Baltimore / Biotechnology / COVID-19

Baltimore County inks agreement with one of its largest employers to buy COVID-19 tests

Medical technology company BD Integrated Diagnostic Solutions will supply up to 2,000 test kits a week. The Sparks-based arm of Beckton, Dickinson and Company shows a pandemic-time contribution from a local biotech force.

COVID-19 testing is among the key areas of need for recovery. (Photo by Flickr user New York National Guard, used under Creative Commons license)

Baltimore County is looking to increase COVID-19 testing capacity with supplies from a medical technology company that is housed in its borders.

On Monday, the County announced an agreement with Sparks-based BD Integrated Diagnostic Solutions (BD IDS) to purchase testing and transport kits. The County will purchase up to 2,000 kits a week, including swabs and vials, with the first run already shipped. The samples will be processed through existing agreements the County has with LabCorp and Quest.

With a policy that allows residents to get tested even if they do not have a doctor’s referral, it’s a move in which the County is seeking to ensure testing supplies are available. A new testing site in Landsdowne also opened on Monday. With more than 7,500 cases, Baltimore County has the third-highest number of COVID-19 infections of any Maryland county, state data shows.

“Ensuring consistent access to testing is a critical component of our long-term fight against this deadly virus,” said County Executive Johnny Olszewski in a statement. “We’re thankful that Baltimore County is able to partner with BD IDS, a business right here in our backyard, to secure testing materials that can be used immediately to enhance our response to COVID-19.”

Along with increasing testing during the pandemic, the news puts a spotlight on a global medical technology company’s local presence. BD IDS is part of prominent medical device company Becton, Dickinson and Company, which has had a presence in the County since 1954. In 2019, BD made the Sparks campus the headquarters for its IDS business, and now has 1,900 employees.

In April, a three-hour test for hospitals that BD IDS scientists developed with Alabama-based BioGX got emergency authorization from the U.S. Food and Drug Administration, and tests were being manufactured at the site, the Baltimore Sun reported. It’s one of the biotech anchors in the state that has jumped into the fight against COVID-19.

Series: Coronavirus

Before you go...

Please consider supporting to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!


Major state funding boost means more Maryland college students can get tech internships

Cal Ripken Jr. essay: The MLB legend explains his drive to build STEM centers in schools across the nation

The end of software as technology

From quantum to biotech, meet this year’s Maryland Tech Council ICON nominees

Technically Media